N a s d a q - V Y N T
H U M A N - P O W E R E D D R U G D I S C O V E R Y
January - 2022
S A F E H A R B O R
This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to Vyant Bio, Inc.'s (formerly Cancer Genetics, Inc.) expectations regarding future financial and/or operating results, and potential for our services, future revenues or growth, or the potential for future strategic collaborations and transactions in this press release constitute forward-looking statements.
Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," and "estimates") should also be considered to be forward-looking statements. Forward- looking statements involve risks and uncertainties, including, without limitation, risks inherent in our attempts to adapt to the global coronavirus pandemic, achieve profitability and increase sales of our pre-clinical services, maintain our existing customer base and avoid cancelation of customer contracts or discontinuance of trials, raise capital to meet our liquidity needs, realize the anticipated benefits of the merger with StemoniX, Inc., and other risks discussed in the Vyant Bio, Inc. Form 10-K for the year ended December 31, 2020, along with other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Vyant Bio, Inc. disclaims any obligation to update these forward-looking statements.
Nasdaq: VYNT | 2 |
DRUG DISCOVERY
Needs a Paradigm Shift | Defines a New Approach |
Underperformance of Widely Used Models for Predicting Drug Efficacy and Safety
Late Introduction of Human Biology in the R&D Process Leads to High Failure and Cost
Deep Expertise and Global Presence in Drug
Discovery
Human Biology and Data Science Driven
Proprietary Discovery Engine
Focused on Efficiently Discovering Novel Therapeutics for Neurological Developmental and Degenerative Diseases
Nasdaq: VYNT | 3 |
Therapeutic Pipeline
Our Therapeutic Assets | IND | |||||
P R E C L I N I C A L | C L I N I C A L | |||||
PROGRAM | INDICATION | EARLY DISCOVERY | TARGET ID & VALIDATION | LEAD ID | LEAD OPTIMIZATION | PHASES 1, 2, 3 |
VYNT-0126 | Rett Syndrome | Vyant Bio | ||||
Partner: Atomwise | ||||||
ORAI-xxxx | Rett Syndrome | |||||
VYNT-xxxx | CDKL5 | Partner: Cyclica | ||||
VYNT-xxxx | Parkinson's Disease | Vyant Bio | ||||
Multiple programs | Vyant Bio | |||||
from early discovery | Multiple Indications |
through pre-clinical
Nasdaq: VYNT | 4 |
Disease Model Assets
Our Platform/Disease Model Assets
DISEASE MODELS | PLATFORMS | PLATFORM & ASSAY DEVELOPMENT | PHENOTYPIC SCREENING | TARGET IDENTIFICATION & VALIDATION | COMPOUND IDENTIFICATION & | |
VALIDATION | ||||||
Undisclosed Partner | microBrain® |
Models | |
Rett Syndrome | microBrain® |
CDKL5 Deficiency | microBrain® |
Disorder | |
Parkinson's Disease | Mid-Brain/Dopaminergic |
Brain Organoid | |
Models Under | Complex Cortical |
Development | Organoids |
Each Organ
Platform
Disease 1 | |
Disease 2 | • Each microOrgan® platform can create hundreds of diseases |
• Each Disease Model can discover multiple therapeutics | |
Disease 3 | |
Disease x
Nasdaq: VYNT | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Vyant Bio Inc. published this content on 10 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 January 2022 13:17:05 UTC.